Strategic testing following toxic epidermal necrolysis allows reintroduction of chemotherapy in a patient with progressive myeloma.

Autor: Goh DSL; Department of Immunology, Concord Hospital, Sydney, Australia., Yuson R; Department of Immunology, Concord Hospital, Sydney, Australia., Gounder P; Department of Haematology, Concord Hospital, Sydney, Australia., Yun J; Department of Immunology, Prince of Wales Hospital, Sydney, Australia., Limaye S; Department of Immunology, Concord Hospital, Sydney, Australia.; University of Sydney, Infectious Diseases and Immunology, Darlington, New South Wales, Australia.
Jazyk: angličtina
Zdroj: Asia Pacific allergy [Asia Pac Allergy] 2024 Jun; Vol. 14 (2), pp. 90-92. Date of Electronic Publication: 2023 Dec 18.
DOI: 10.5415/apallergy.0000000000000125
Abstrakt: Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome belong to a family of severe cutaneous adverse reactions that can be life-threatening and carry a risk of significant morbidity and potential mortality in the event of re-exposure. Lifelong avoidance of the culprit agent is mandated, which can lead to the exclusion of multiple medications if the trigger is unclear. This can result in adverse health outcomes analogous to that of a penicillin allergy label. We present a case in which the patient would progress to fatal myeloma in the absence of treatment, however, multiple medications were administered prior to the occurrence of TEN following previous chemotherapy. Available risk stratification tools including human leucocyte antigen assessment and the algorithm of drug causality for epidermal necrolysis scoring system were utilized followed by patch testing which identified a lesser-suspected agent as possibly causative. Further evidence-based in vivo testing and subsequent challenges allowed for the reintroduction of life-saving chemotherapy.
Competing Interests: The authors have no financial conflicts of interest.
(Copyright © 2023. Asia Pacific Association of Allergy, Asthma and Clinical Immunology.)
Databáze: MEDLINE